An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 1400 participants.

Also called NCT05667493

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05667493
  • EudraCT 2022-000826-74
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Poland, Portugal, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT05667493. Allocation not applicable; no masking; primary purpose treatment. Start 2022-11-30 (actual); primary completion 2029-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Condition
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Intervention (Drug)
Eplontersen
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct05667493
Content hash
96d890cda173166313236a2c3ef45520545f1e43a0206947cdb8673a0e055d6f